Indeed, in an orthotopic model of breast cancer, the tumour-draining LN-targeted administration of immunotherapeutic agents (anti-CTLA-4 and anti-PD-1) is sufficient to suppress tumour growth to the same level as intratumoural administration and to a higher level than systemic administration [150]. This evidence concerns the gene CTLA4 and breast cancer.